-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 6, 2022, Eli Lilly and Company announced that it has acquired exclusive rights to Entos Pharmaceuticals' proprietary Fusogenix nucleic acid delivery technology platform to develop and commercialize nucleic acid therapeutics targeting the central and peripheral nervous systems
.
The press release states that Fusogenix proteo-lipid vehicles (PLV), an innovative delivery technology, has the potential to overcome key delivery challenges for nucleic acid therapeutic modalities
The rapid development of nucleic acid therapy in recent years has offered hope for a cure for many previously untreatable diseases
.
A variety of gene therapies are under development with the promise of eradicating genetic diseases, halting cancer and reversing aging
Fusogenix proteolipid carriers are composed of well-tolerated neutral lipids, and specialized fusion-associated small transmembrane proteins (FASTs), enabling efficient fusion and intracellular delivery of therapeutic nucleic acid payloads
.
This PLV platform combines the low toxicity profile of neutral lipid formulations with the high efficiency of fusion protein-mediated delivery technology
It still shows good safety at the dose level of effective human dose
.
Tolerability studies showed that even at very high doses, no adverse pathology was reported, either in the main organs of uptake of the therapy, or in the liver and spleen
In this collaboration, Entos will be responsible for generating, developing and optimizing PLVs utilizing its proprietary Fusogenix technology platform
.
Eli Lilly will select specific PLVs for further clinical development and commercialization
References:
References:[1] Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications.
[1] Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications.
[2] You know AAV and LNP.
What about PLV? Eli Lilly lines up new vehicle to deliver its genetic medicines.
Retrieved January 6, 2022, from https://endpts.
com/you-know-aav-and-lnp- what-about-plv-eli-lilly-lines-up-new-vehicle-to-deliver-its-genetic-medicines/
